Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2016Journal of Crohn s and Colitis

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLisa SmitsPharmo InstituteLDLauranne DerikxErasmus MCDJDirk J. de JongRadboud University Nijmegen

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smits et al. (2016) studied this question.

synapsesocial.com/papers/6aa7c45efff91a8cdd9f14bfhttps://doi.org/10.1093/ecco-jcc/jjw087
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of CT‐P13 , a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study2015 · 176 citations
  2. 2Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort2015 · 183 citations
  3. 3Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis2006 · 472 citations
  4. 4The MOS 36-Item Short-Form Health Survey (SF-36)1993 · 6,715 citations
  5. 5ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)2013 · 193 citations